{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+PD%28L%29-1", "query": { "intervention": "Standard of Care PD(L)-1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+PD%28L%29-1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T03:10:30.835Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03329248", "title": "QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "lovaza", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2017-11-06", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329248" }, { "nct_id": "NCT07250477", "title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Stage IIIC", "Non-small Cell Lung Cancer Stage IV", "Non Small Cell Lung Cancer", "Non-small Cell Lung Cancer Metastatic", "Non-small Cell Lung Cancer Unresectable" ], "interventions": [ { "name": "Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2026-01-30", "completion_date": "2036-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 4, "location_summary": "Chico, California • Marysville, California • Sacramento, California + 1 more", "locations": [ { "city": "Chico", "state": "California" }, { "city": "Marysville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Truckee", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250477" }, { "nct_id": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Hormone-Resistant Breast Cancer", "Non Small Cell Lung Cancer", "Mesothelioma" ], "interventions": [ { "name": "AG-01 Compound", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "A&G Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2022-02-14", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2022-11-28", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627960" }, { "nct_id": "NCT06603844", "title": "First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "CRB-601 monoclonal antibody", "type": "DRUG" }, { "name": "Anti-PD-1 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corbus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2024-12-04", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06603844" }, { "nct_id": "NCT01661881", "title": "Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christine Ryan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 23, "start_date": "2012-08-16", "completion_date": "2030-04", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661881" }, { "nct_id": "NCT05450692", "title": "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 594, "start_date": "2022-09-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 27, "location_summary": "Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450692" }, { "nct_id": "NCT03877250", "title": "Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Pre-Treatment Biopsy", "type": "DIAGNOSTIC_TEST" }, { "name": "On-Treatment Biopsy", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy at Disease Progression", "type": "DIAGNOSTIC_TEST" }, { "name": "Peripheral Blood-Based Studies", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-03-08", "completion_date": "2020-08-26", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03877250" }, { "nct_id": "NCT03697304", "title": "Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasm Metastasis", "Advanced Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "Ezabenlimab", "type": "DRUG" }, { "name": "BI 754111", "type": "DRUG" }, { "name": "BI 836880", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2019-03-19", "completion_date": "2024-12-03", "has_results": true, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 11, "location_summary": "La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697304" }, { "nct_id": "NCT05657873", "title": "A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Non-small Cell Carcinoma", "NSCLC", "NSCLC Stage IV" ], "interventions": [ { "name": "L-SABR", "type": "RADIATION" }, { "name": "Anti-PD-(L)1 based immunotherapy", "type": "BIOLOGICAL" }, { "name": "Platinum based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2022-12-09", "completion_date": "2026-12-09", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 9, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657873" }, { "nct_id": "NCT06524544", "title": "A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2025-12-02", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-01T03:10:30.835Z", "location_count": 161, "location_summary": "Phoenix, Arizona • Irvine, California • Orange, California + 126 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06524544" } ] }